Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥3,995 JPY
Change Today +5.00 / 0.13%
Volume 434.0K
4516 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
As of 2:00 AM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

nippon shinyaku co ltd (4516) Snapshot

Open
¥4,000
Previous Close
¥3,990
Day High
¥4,015
Day Low
¥3,945
52 Week High
03/13/15 - ¥4,790
52 Week Low
05/9/14 - ¥1,790
Market Cap
280.7B
Average Volume 10 Days
307.1K
EPS TTM
¥91.86
Shares Outstanding
70.3M
EX-Date
03/27/15
P/E TM
43.5x
Dividend
¥25.00
Dividend Yield
0.63%
Current Stock Chart for NIPPON SHINYAKU CO LTD (4516)

Related News

No related news articles were found.

nippon shinyaku co ltd (4516) Related Businessweek News

No Related Businessweek News Found

nippon shinyaku co ltd (4516) Details

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs. The company offers drugs for pain, inflammation, and allergies; hematologic malignancies; urological diseases; gastrointestinal disorders; cardiovascular and metabolic diseases; and other diseases. Its products include Tramal for cancer and chronic pain; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid; Livostin for allergic rhinitis and conjunctivitis; Hypen, a non-steroidal anti-inflammatory and analgesic agent; Zalutia for urinary disorder caused by benign prostatic; Cialis for erectile dysfunction; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; Trisenox for relapsed and refractory acute promyelocytic leukemia; and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company’s products also include Gaslon N for gastric ulcer and gastritis; Portolac, an antihyperammonemia agent; Adcirca for pulmonary arterial hypertension; Selectol, a vasodilating beta-1 blocker; Regtect for maintaining alcohol abstinence; Lunabell for dysmenorrhea; and Cephadol for vertigo. The company is also involved in the research and development, and marketing of drugs in the areas of urology, hematology, gynecology, otolaryngology, and orthopedics. In addition, it provides functional foods, including health food ingredients, preservatives/shelf life improvers, protein preparations, and spice and condiments. The company was founded in 1911 and is headquartered in Kyoto, Japan.

1,790 Employees
Last Reported Date: 06/30/14
Founded in 1911

nippon shinyaku co ltd (4516) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nippon shinyaku co ltd (4516) Key Developments

Nippon Shinyaku Co. Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2014; Provides Earnings and Dividend Guidance for the Year Ending March 31, 2015

Nippon Shinyaku Co. Ltd. reported consolidated earnings results for the nine months ended December 31, 2014. For the period, the company reported net sales of JPY 58,690 million against JPY 55,813 million a year ago. Operating income was JPY 5,997 million against JPY 5,425 million a year ago. Ordinary income was JPY 6,444 million against JPY 5,950 million a year ago. Net income was JPY 4,340 million or JPY 64.39 per basic share against JPY 3,899 million or JPY 57.80 per basic share a year ago. Income before income taxes and minority interests was JPY 6,444 million against JPY 5,950 million a year ago. For the year ending March 31, 2015, the company expects net sales of JPY 81,000 million, operating income of JPY 8,500 million, ordinary income of JPY 8,700 million and net income of JPY 6,000 million or JPY 89.03 per share. For the year ending March 31, 2015, the company expects to pay dividend of JPY 13.00 per share against JPY 12.00 per share a year ago.

Nippon Shinyaku Co. Ltd. to Report Q3, 2015 Results on Feb 06, 2015

Nippon Shinyaku Co. Ltd. announced that they will report Q3, 2015 results on Feb 06, 2015

Nippon Shinyaku Co. Ltd., Q3 2015 Earnings Call, Feb 06, 2015

Nippon Shinyaku Co. Ltd., Q3 2015 Earnings Call, Feb 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4516:JP ¥3,995.00 JPY +5.00

4516 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.126.10 CHF +2.10
United Therapeutics Corp $169.52 USD -1.40
View Industry Companies
 

Industry Analysis

4516

Industry Average

Valuation 4516 Industry Range
Price/Earnings 43.3x
Price/Sales 3.4x
Price/Book 2.8x
Price/Cash Flow 42.8x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NIPPON SHINYAKU CO LTD, please visit www.nippon-shinyaku.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.